NASDAQ:BNR

Burning Rock Biotech Competitors

$26.14
0.00 (0.00 %)
(As of 05/11/2021 12:00 AM ET)
Add
Compare
Today's Range
$25.19
$27.75
50-Day Range
$25.13
$30.60
52-Week Range
$18.64
$39.75
Volume232,543 shs
Average Volume343,180 shs
Market Capitalization$2.73 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Burning Rock Biotech (NASDAQ:BNR) Vs. NTRA, NVTA, CDNA, VCYT, FLGT, and GTH

Should you be buying BNR stock or one of its competitors? Companies in the industry of "medical laboratories" are considered alternatives and competitors to Burning Rock Biotech, including Natera (NTRA), Invitae (NVTA), CareDx (CDNA), Veracyte (VCYT), Fulgent Genetics (FLGT), and Genetron (GTH).

Natera (NASDAQ:NTRA) and Burning Rock Biotech (NASDAQ:BNR) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, valuation, analyst recommendations, dividends, risk and institutional ownership.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Natera and Burning Rock Biotech, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Natera01902.90
Burning Rock Biotech00303.00

Natera presently has a consensus target price of $114.70, indicating a potential upside of 27.09%. Burning Rock Biotech has a consensus target price of $32.30, indicating a potential upside of 23.57%. Given Natera's higher possible upside, equities analysts clearly believe Natera is more favorable than Burning Rock Biotech.

Valuation and Earnings

This table compares Natera and Burning Rock Biotech's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Natera$302.33 million26.16$-124,830,000.00($1.99)-45.35
Burning Rock BiotechN/AN/AN/AN/AN/A

Burning Rock Biotech has lower revenue, but higher earnings than Natera.

Profitability

This table compares Natera and Burning Rock Biotech's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Natera-52.11%-53.39%-25.89%
Burning Rock BiotechN/AN/AN/A

Institutional and Insider Ownership

94.9% of Natera shares are held by institutional investors. Comparatively, 15.8% of Burning Rock Biotech shares are held by institutional investors. 9.3% of Natera shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Natera beats Burning Rock Biotech on 5 of the 9 factors compared between the two stocks.

Invitae (NYSE:NVTA) and Burning Rock Biotech (NASDAQ:BNR) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, earnings, analyst recommendations and profitability.

Profitability

This table compares Invitae and Burning Rock Biotech's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Invitae-183.50%-81.19%-37.28%
Burning Rock BiotechN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Invitae and Burning Rock Biotech, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Invitae03402.57
Burning Rock Biotech00303.00

Invitae presently has a consensus price target of $46.1667, suggesting a potential upside of 65.00%. Burning Rock Biotech has a consensus price target of $32.30, suggesting a potential upside of 23.57%. Given Invitae's higher probable upside, equities research analysts plainly believe Invitae is more favorable than Burning Rock Biotech.

Institutional and Insider Ownership

78.6% of Invitae shares are owned by institutional investors. Comparatively, 15.8% of Burning Rock Biotech shares are owned by institutional investors. 2.9% of Invitae shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Invitae and Burning Rock Biotech's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Invitae$216.82 million25.79$-241,960,000.00($2.28)-12.27
Burning Rock BiotechN/AN/AN/AN/AN/A

Burning Rock Biotech has lower revenue, but higher earnings than Invitae.

Summary

Invitae beats Burning Rock Biotech on 5 of the 9 factors compared between the two stocks.

CareDx (NASDAQ:CDNA) and Burning Rock Biotech (NASDAQ:BNR) are both mid-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings.

Profitability

This table compares CareDx and Burning Rock Biotech's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CareDx-11.79%-10.95%-7.94%
Burning Rock BiotechN/AN/AN/A

Analyst Ratings

This is a breakdown of current ratings for CareDx and Burning Rock Biotech, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
CareDx01413.00
Burning Rock Biotech00303.00

CareDx presently has a consensus price target of $75.6667, suggesting a potential upside of 15.08%. Burning Rock Biotech has a consensus price target of $32.30, suggesting a potential upside of 23.57%. Given Burning Rock Biotech's higher possible upside, analysts plainly believe Burning Rock Biotech is more favorable than CareDx.

Insider and Institutional Ownership

15.8% of Burning Rock Biotech shares are held by institutional investors. 3.1% of CareDx shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares CareDx and Burning Rock Biotech's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CareDx$127.07 million26.93$-21,970,000.00($0.52)-126.44
Burning Rock BiotechN/AN/AN/AN/AN/A

Burning Rock Biotech has lower revenue, but higher earnings than CareDx.

Summary

Burning Rock Biotech beats CareDx on 5 of the 9 factors compared between the two stocks.

Veracyte (NASDAQ:VCYT) and Burning Rock Biotech (NASDAQ:BNR) are both mid-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, valuation, risk, dividends and analyst recommendations.

Earnings & Valuation

This table compares Veracyte and Burning Rock Biotech's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Veracyte$120.37 million22.28$-12,600,000.00($0.27)-147.74
Burning Rock BiotechN/AN/AN/AN/AN/A

Burning Rock Biotech has lower revenue, but higher earnings than Veracyte.

Analyst Recommendations

This is a summary of current recommendations for Veracyte and Burning Rock Biotech, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Veracyte11602.63
Burning Rock Biotech00303.00

Veracyte presently has a consensus price target of $58.4286, indicating a potential upside of 46.47%. Burning Rock Biotech has a consensus price target of $32.30, indicating a potential upside of 23.57%. Given Veracyte's higher probable upside, equities research analysts clearly believe Veracyte is more favorable than Burning Rock Biotech.

Institutional and Insider Ownership

15.8% of Burning Rock Biotech shares are owned by institutional investors. 8.3% of Veracyte shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Veracyte and Burning Rock Biotech's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Veracyte-30.46%-12.27%-10.95%
Burning Rock BiotechN/AN/AN/A

Summary

Burning Rock Biotech beats Veracyte on 5 of the 9 factors compared between the two stocks.

Burning Rock Biotech (NASDAQ:BNR) and Fulgent Genetics (NASDAQ:FLGT) are both mid-cap business services companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, earnings, risk, institutional ownership and valuation.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Burning Rock Biotech and Fulgent Genetics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Burning Rock Biotech00303.00
Fulgent Genetics12202.20

Burning Rock Biotech presently has a consensus price target of $32.30, indicating a potential upside of 23.57%. Fulgent Genetics has a consensus price target of $74.40, indicating a potential upside of 6.26%. Given Burning Rock Biotech's stronger consensus rating and higher possible upside, analysts clearly believe Burning Rock Biotech is more favorable than Fulgent Genetics.

Valuation & Earnings

This table compares Burning Rock Biotech and Fulgent Genetics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Burning Rock BiotechN/AN/AN/AN/AN/A
Fulgent Genetics$32.53 million62.40$-410,000.00$0.023,501.00

Burning Rock Biotech has higher earnings, but lower revenue than Fulgent Genetics.

Profitability

This table compares Burning Rock Biotech and Fulgent Genetics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Burning Rock BiotechN/AN/AN/A
Fulgent Genetics35.31%43.81%36.82%

Insider & Institutional Ownership

15.8% of Burning Rock Biotech shares are held by institutional investors. Comparatively, 33.4% of Fulgent Genetics shares are held by institutional investors. 45.0% of Fulgent Genetics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Fulgent Genetics beats Burning Rock Biotech on 6 of the 9 factors compared between the two stocks.

Genetron (NASDAQ:GTH) and Burning Rock Biotech (NASDAQ:BNR) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, valuation, earnings and dividends.

Valuation and Earnings

This table compares Genetron and Burning Rock Biotech's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genetron$45.68 million35.23$-95,470,000.00N/AN/A
Burning Rock BiotechN/AN/AN/AN/AN/A

Burning Rock Biotech has lower revenue, but higher earnings than Genetron.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Genetron and Burning Rock Biotech, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Genetron00203.00
Burning Rock Biotech00303.00

Genetron presently has a consensus target price of $19.50, indicating a potential upside of 7.68%. Burning Rock Biotech has a consensus target price of $32.30, indicating a potential upside of 23.57%. Given Burning Rock Biotech's higher possible upside, analysts plainly believe Burning Rock Biotech is more favorable than Genetron.

Profitability

This table compares Genetron and Burning Rock Biotech's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
GenetronN/AN/AN/A
Burning Rock BiotechN/AN/AN/A

Institutional and Insider Ownership

19.6% of Genetron shares are owned by institutional investors. Comparatively, 15.8% of Burning Rock Biotech shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.


Burning Rock Biotech Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Natera logo
NTRA
Natera
1.7$90.25flat$7.91 billion$302.33 million-37.92Earnings Announcement
Analyst Report
Invitae logo
NVTA
Invitae
1.6$27.98flat$5.59 billion$216.82 million-7.19Analyst Report
Gap Down
CareDx logo
CDNA
CareDx
1.2$65.75flat$3.42 billion$127.07 million-142.93Earnings Announcement
Gap Down
Veracyte logo
VCYT
Veracyte
1.4$39.89flat$2.68 billion$120.37 million-57.81Earnings Announcement
Analyst Report
News Coverage
Gap Down
Fulgent Genetics logo
FLGT
Fulgent Genetics
1.4$70.02flat$2.03 billion$32.53 million34.66Earnings Announcement
Gap Down
GTH
Genetron
0.4$18.11flat$1.61 billion$45.68 million0.00
Castle Biosciences logo
CSTL
Castle Biosciences
1.9$54.56flat$1.37 billion$51.87 million-320.92Earnings Announcement
Analyst Upgrade
Gap Down
RadNet logo
RDNT
RadNet
1.3$23.96flat$1.25 billion$1.15 billion-114.09Earnings Announcement
Renalytix AI logo
RNLX
Renalytix AI
0.7$27.61flat$994.62 millionN/A-172.56Gap Down
DermTech logo
DMTK
DermTech
1.6$33.27flat$961.70 million$3.36 million-19.69Upcoming Earnings
Analyst Report
Gap Down
Personalis logo
PSNL
Personalis
1.6$19.46flat$854.45 million$65.21 million-18.36Earnings Announcement
Analyst Revision
Gap Down
Celcuity logo
CELC
Celcuity
1.0$25.92flat$318.51 millionN/A-30.49Earnings Announcement
Upcoming Earnings
Exagen logo
XGN
Exagen
1.7$15.06flat$190.81 million$40.39 million-1.23Gap Down
Centogene logo
CNTG
Centogene
1.2$9.05flat$179.74 million$54.64 million-6.20
Progenity logo
PROG
Progenity
1.8$2.50flat$150.86 millionN/A0.00Upcoming Earnings
News Coverage
Enzo Biochem logo
ENZ
Enzo Biochem
0.7$2.96flat$142.76 million$76.02 million-6.88Gap Down
OpGen logo
OPGN
OpGen
1.3$2.27flat$86.86 million$3.50 million-1.12Upcoming Earnings
Gap Down
Biocept logo
BIOC
Biocept
1.2$4.68flat$62.73 million$5.53 million-1.16Gap Down
AnPac Bio-Medical Science logo
ANPC
AnPac Bio-Medical Science
0.7$4.41flat$49.40 million$1.56 million-2.72Upcoming Earnings
Gap Down
Psychemedics logo
PMD
Psychemedics
0.8$6.66flat$36.87 million$37.68 million-9.65
AMS
American Shared Hospital Services
0.1$2.76flat$16.01 million$20.60 million-27.60High Trading Volume
This page was last updated on 5/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.